Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CCR1 | P32246 | 4/20 | 0.50 |
| ▸ | CCR8 | P51685 | 4/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064745 | 0.79 | MAPT (0.55) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL9803225 | 0.79 | MAPT (0.55) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL88110 | 0.79 | LMNA (0.50) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL29740308 | 0.79 | LMNA (0.50) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL10656134 | 0.78 | MAPT (0.48) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL29740307 | 0.78 | LMNA (0.48) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL9803452 | 0.76 | MAPT (0.46) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL5514516 | 0.73 | MAPT (0.47) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL3822260 | 0.73 | CA1 (0.50) | LMNAMAPTCCR1CCR8CCR5 | |
| SCHEMBL35938 | 0.71 | LMNA (0.54) | LMNAMAPTCCR1CCR8CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763677-B1 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-9873694-B2 | Imidazole quinoline-based immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20140242121-A1 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2763677-A2 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS | Janus Biotherapeutics, Inc. (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052550-A2 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-0700913-B1 | 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds | HOECHST MARION ROUSSEL INC (US) | 1998-06-03 | — | — | EP | disclosed |
| US-5563272-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5500423-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0700913-A1 | 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140242121-A1 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS | IRF3, HLA-DRB1, IFNG | LMNA 4593/4885MAPT 12/4885CCR1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.